Fatal interstitial pneumonitis associated with sirolimus therapy in a heart transplant recipient

Interstitial pneumonitis is a temporary side effect of sirolimus therapy and has been described mainly in renal transplant recipients. It is considered to be dose dependent and has been documented in patients receiving at least 5 mg daily, or in patients with blood concentration plateaus >15 ng/m...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of heart and lung transplantation Vol. 23; no. 6; pp. 780 - 782
Main Authors Manito, Nicolás, Kaplinsky, Edgardo J, Bernat, Roger, Roca, Josep, Castells, Eduardo, Serrano, Teresa, Esplugas, Enrique
Format Journal Article
LanguageEnglish
Published New York, NY Elsevier Inc 01.06.2004
Elsevier Science
Subjects
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Biological and medical sciences
Dose-Response Relationship, Drug
Fatal Outcome
Heart Transplantation
Humans
Immunosuppressive Agents - administration & dosage
Immunosuppressive Agents - adverse effects
Lung Diseases, Interstitial - chemically induced
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Pneumology
Respiratory system : syndromes and miscellaneous diseases
Sirolimus - administration & dosage
Sirolimus - adverse effects
Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
Surgery of the heart
Heart
Lung disease
Sirolimus
Respiratory disease
Cardiovascular disease
Transplantation
Homotransplantation
Antibiotic
Association
Treatment
Surgery
Interstitial pneumonitis
Graft
Immunosuppressive agent
Antibacterial agent
Online AccessGet full text

Cover

More Information
Summary:Interstitial pneumonitis is a temporary side effect of sirolimus therapy and has been described mainly in renal transplant recipients. It is considered to be dose dependent and has been documented in patients receiving at least 5 mg daily, or in patients with blood concentration plateaus >15 ng/ml. In general, clinical and radiologic features improve after discontinuation and, to the best of our knowledge, no reports of fatalities have been published. Our report documents the death in a heart transplant recipient (52-year-old man) that resulted from a loading-dose administration (15 mg), and we report the association of persistently increased blood concentrations (>20 ng/ml) during most of the scheduled administration period.
ISSN:1053-2498
1557-3117
DOI:10.1016/j.healun.2003.07.008